Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Transcranial Sonography and Machine Learning for Schizophrenia Identification (TCS-ML-SZ)

17 de mayo de 2026 actualizado por: Xiaocheng Zhang, Taizhou Second People's Hospital

Development and Validation of an Early Prediction Model for Schizophrenia Integrating Transcranial Sonography Structural Imaging and Machine Learning

Schizophrenia is a serious mental illness. Doctors usually diagnose schizophrenia by talking with patients, reviewing symptoms, and using clinical assessment. In early or less typical cases, diagnosis may be difficult.

This study will look at whether brain ultrasound information can help doctors identify features related to schizophrenia. The ultrasound scan used in this study is called transcranial sonography. It is a non-invasive scan that uses sound waves to look at brain structures through natural thin areas of the skull.

The study will include adults with schizophrenia and adults without a personal or family history of mental disorders. All participants will have a transcranial sonography scan and provide basic clinical information. The researchers will measure brain ultrasound features, including the substantia nigra, raphe nuclei, and third ventricle, and will combine these features with clinical information.

The main question is whether a computer model using ultrasound and clinical information can help distinguish adults with schizophrenia from adults without schizophrenia. The model is intended only as a research tool and possible future aid for doctors. It will not replace diagnosis by a psychiatrist and will not change the participant's usual medical care.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

This is a prospective observational case-control study designed to develop and evaluate a machine-learning model for identifying schizophrenia using transcranial sonography (TCS) structural imaging features and clinical information.

Schizophrenia is clinically heterogeneous, and diagnosis depends mainly on clinical symptoms and psychiatric assessment. TCS is a non-invasive imaging method that can assess selected deep brain structures through the temporal acoustic window. Previous studies suggest that ultrasound features of structures such as the substantia nigra, raphe nuclei, and third ventricle may be related to neuropsychiatric disorders. This study will investigate whether TCS-derived structural imaging features, combined with clinical variables, can support auxiliary identification of schizophrenia.

Adults aged 18 to 65 years with schizophrenia diagnosed according to ICD-10 criteria and matched adults without a personal or family history of psychiatric disorders will be enrolled. The planned enrollment is 200 participants, including approximately 100 participants with schizophrenia and 100 healthy controls. Participants will undergo baseline TCS assessment and clinical data collection. No therapeutic intervention will be assigned by the investigators, and participation will not replace or alter usual clinical care.

TCS assessments will focus on selected brain structural imaging features, including substantia nigra echogenicity, raphe nuclei echogenicity, and third-ventricle width. Clinical information may include demographic characteristics, medical history, family history, disease course, medication history, and symptom assessment data when available. TCS measurements will be performed according to a standardized procedure, and image quality control will be conducted to reduce measurement variability.

The collected TCS and clinical variables will be integrated into a structured dataset for model development. Candidate machine-learning methods may include logistic regression, random forest, support vector machine, and XGBoost. Feature selection and model optimization will be performed within the model development process. Internal validation will be used to assess model performance, and additional independent data may be used for external validation if available.

Model performance will be evaluated using discrimination, calibration, and clinical utility metrics, including the area under the receiver operating characteristic curve, sensitivity, specificity, accuracy, F1 score, calibration assessment, and decision curve analysis where appropriate. Model interpretability will be explored using SHAP to assess the relative contribution of TCS imaging features and clinical variables.

The resulting model is intended as an auxiliary research tool for schizophrenia identification. It is not intended to make a definitive diagnosis, replace psychiatric assessment, or guide treatment decisions independently.

Tipo de estudio

De observación

Inscripción (Estimado)

200

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Xiaochen Zhang
  • Número de teléfono: +8615967690053
  • Correo electrónico: 15967690053@163.com

Ubicaciones de estudio

    • Zhejiang
      • Taizhou, Zhejiang, Porcelana, 317200
        • Taizhou Second People's Hospital
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Método de muestreo

Muestra no probabilística

Población de estudio

Adults aged 18 to 65 years will be recruited from Taizhou Second People's Hospital and related recruitment channels. The study population will include participants with schizophrenia diagnosed according to ICD-10 criteria and healthy control participants without a personal or family history of psychiatric disorders. Healthy controls will be matched as far as possible to the schizophrenia group by basic demographic characteristics. All participants will undergo baseline transcranial sonography assessment and clinical data collection.

Descripción

Inclusion Criteria:

Schizophrenia group:

  1. Adults aged 18 to 65 years.
  2. Diagnosis of schizophrenia according to ICD-10 criteria by a psychiatrist.
  3. Able to complete clinical assessment and transcranial sonography examination.
  4. No other severe physical disease, neurological disease, or major psychiatric disorder.
  5. Written informed consent provided by the participant or legally authorized representative.

Healthy control group:

  1. Adults aged 18 to 65 years.
  2. No personal history of psychiatric disorders.
  3. No family history of psychiatric disorders.
  4. No severe physical disease, neurological disease, or major psychiatric disorder.
  5. Basic demographic characteristics matched as far as possible to the schizophrenia group.
  6. Able to complete clinical assessment and transcranial sonography examination.
  7. Written informed consent provided by the participant or legally authorized representative.

Exclusion Criteria:

  1. Severe physical disease or neurological disease.
  2. History of drug or alcohol abuse.
  3. Inability to complete clinical assessment or transcranial sonography examination.
  4. Inadequate temporal acoustic window or poor image quality preventing valid transcranial sonography measurements.
  5. Acute or clinically unstable state that prevents completion of study procedures.
  6. Comorbid major psychiatric disorder, such as major depressive disorder.
  7. Refusal or withdrawal of informed consent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Schizophrenia Group
Adults aged 18 to 65 years with schizophrenia diagnosed according to ICD-10 criteria. Participants will undergo baseline transcranial sonography assessment and clinical data collection.
Baseline transcranial sonography assessment of brain structural imaging features, including substantia nigra echogenicity, raphe nuclei echogenicity, and third-ventricle width.
Healthy Control Group
Adults aged 18 to 65 years without a personal or family history of psychiatric disorders and matched as far as possible to the schizophrenia group by basic demographic characteristics. Participants will undergo baseline transcranial sonography assessment and clinical data collection.
Baseline transcranial sonography assessment of brain structural imaging features, including substantia nigra echogenicity, raphe nuclei echogenicity, and third-ventricle width.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Area Under the ROC Curve of the Final TCS-Clinical Model
Periodo de tiempo: Baseline; analyzed after completion of baseline data collection
The area under the receiver operating characteristic curve will be used to assess the ability of the final machine-learning model, based on transcranial sonography and clinical variables, to distinguish participants with ICD-10 schizophrenia from healthy controls. The reference standard will be clinical diagnosis according to ICD-10 criteria.
Baseline; analyzed after completion of baseline data collection

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sensitivity and Specificity of the Final TCS-Clinical Model
Periodo de tiempo: Baseline; analyzed after completion of baseline data collection
Sensitivity and specificity will be calculated for the final model for distinguishing participants with schizophrenia from healthy controls, using a pre-specified or internally optimized classification threshold.
Baseline; analyzed after completion of baseline data collection
Other Classification Performance Metrics of the Final Model
Periodo de tiempo: Baseline; analyzed after completion of baseline data collection
Accuracy, precision, recall, and F1 score will be calculated to further evaluate the classification performance of the final model for distinguishing participants with schizophrenia from healthy controls.
Baseline; analyzed after completion of baseline data collection
Calibration Performance of the Final TCS-Clinical Model
Periodo de tiempo: Baseline; analyzed after completion of baseline data collection
Calibration will be evaluated by comparing predicted probabilities with observed diagnostic status using calibration plots, calibration slope, calibration intercept, and/or Brier score, as appropriate.
Baseline; analyzed after completion of baseline data collection

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de junio de 2026

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

17 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de mayo de 2026

Publicado por primera vez (Actual)

22 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

The individual participant data generated or analyzed during this study will not be publicly shared because of participant privacy, the sensitive nature of psychiatric clinical data, and restrictions in the ethics approval and informed consent. Aggregated results will be reported in the published article.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Transcranial Sonography

Suscribir